Since CLL is characterized by various genomic aberrations, including deletion of the short arm of chromosome 17 and/or TP53 mutations, their presence or absence determines the treatment pathway, namely the choice between CIT and targeted therapies. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.